Clinical trial
Biological Therapy in Treating Patients With Glioblastoma Multiforme
NCT00003185 · The Cleveland Clinic, Other · Completed
Key facts
| NCT number | NCT00003185 |
|---|---|
| Title | Biological Therapy in Treating Patients With Glioblastoma Multiforme |
| Official title | Adoptive Immunotherapy of Glioblastoma Multiforme With Tumor-Sensitized, Ex Vivo Activated T Lymphocytes |
| Lead sponsor | The Cleveland Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological, Drug, Procedure |
| Interventions | autologous tumor cell vaccine, sargramostim, tumor-draining lymph node lymphocyte therapy, cyclophosphamide, conventional surgery |
| Enrollment | 40 |
| Start date | Aug 1, 1997 |
| Completion | Jul 1, 1998 |
| First posted | Feb 9, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: